Clinical Trials List
2023-09-01 - 2031-12-31
Phase III
Not yet recruiting3
Recruiting1
ICD-10C43.9
Malignant melanoma of skin, unspecified
ICD-10D03.9
Melanoma in situ, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9172.9
Malignant melanoma of skin, site unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 陳彥豪 無
- Chih-Hung Lee 無
- Tai-Jan Chiu 無
- Shau-Hsuan Li 無
- 林偉雄 無
- 郭明濬 無
- 常景棣 無
- 林尚宏 無
- 劉建廷 無
- 陳彥仰 無
- 吳佳哲 無
- 黃詩喻 無
- 林昶廷 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Tak-Wah Wong 無
- Shin-Chen Pan 無
- 顏志傑 無
- 劉奕廷 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chia-Hsun Hsieh 無
- 黃彥霖 無
- 吳教恩 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 廖肇裕 無
- 徐偉勛 無
- YI-HUA LIAO 無
- 沈宜萱 無
- Jih-Hsiang Lee 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
1089 participants
